Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Multicenter, open-label Phase I dose-escalation and dose-expansion study of APG-5918 in patients with advanced solid tumors or hematologic malignancies

Next Previous
Search
Trial Profile

Multicenter, open-label Phase I dose-escalation and dose-expansion study of APG-5918 in patients with advanced solid tumors or hematologic malignancies

Status: Planning
Phase of Trial: Phase I

Latest Information Update: 16 Nov 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs APG-5918 (Primary)
  • Indications Haematological malignancies; Solid tumours
  • Focus Adverse reactions

    • Most Recent Events

    • 16 Nov 2022 New trial record
    • 09 Nov 2022 According to an Ascentage Pharma media release, Prof. Ruihua Xu is the principal investigator of this study.
    • 09 Nov 2022 According to an Ascentage Pharma media release, APG-5918 has been approved by the Center for Drug Evaluation (CDE) of China National Medical Products Administration (NMPA) to initiate this study.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top